Login / Signup

Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.

Tomohiro NishinaTomoko FujitaNaoto YoshizukaKo SugibayashiKosho MurayamaYasutoshi Kuboki
Published in: BMJ open (2022)
NCT03394144; ClinicalTrials.gov.
Keyphrases
  • open label
  • clinical trial
  • placebo controlled
  • cell proliferation
  • study protocol
  • double blind
  • cancer therapy
  • combination therapy
  • drug delivery